|
1
|
O'Neill S and Cervera R: Systemic lupus
erythematosus. Best Pract Res Clin Rheumatol. 24:841–855. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kasitanon N, Magder LS and Petri M:
Predictors of survival in systemic lupus erythematosus. Medicine
(Baltimore). 85:147–156. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ward MM, Pyun E and Studenski S: Causes of
death in systemic lupus erythematosus. Long-term followup of an
inception cohort. Arthritis Rheum. 38:1492–1499. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zen M, Iaccarino L, Gatto M, Bettio S,
Nalotto L, Ghirardello A, Punzi L and Doria A: Prolonged remission
in Caucasian patients with SLE: Prevalence and outcomes. Ann Rheum
Dis. 74:2117–2122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lloyd W and Schur PH: Immune complexes,
complement, and anti-DNA in exacerbations of systemic lupus
erythematosus (SLE). Medicine (Baltimore). 60:208–217. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kao AH, Navratil JS, Ruffing MJ, Liu CC,
Hawkins D, McKinnon KM, Danchenko N, Ahearn JM and Manzi S:
Erythrocyte C3d and C4d for monitoring disease activity in systemic
lupus erythematosus. Arthritis Rheum. 62:837–844. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bootsma H, Spronk PE, Ter Borg EJ, Hummel
EJ, de Boer G, Limburg PC and Kallenberg CG: The predictive value
of fluctuations in IgM and IgG class anti-dsDNA antibodies for
relapses in systemic lupus erythematosus. A prospective long-term
observation. Ann Rheum Dis. 56:661–666. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wong CK, Wong PT, Tam LS, Li EK, Chen DP
and Lam CW: Activation profile of Toll-like receptors of peripheral
blood lymphocytes in patients with systemic lupus erythematosus.
Clin Exp Immunol. 159:11–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wu O, Chen GP, Chen H, Li XP, Xu JH, Zhao
SS, Sheng J, Feng JB, Cai J, Fang XH, et al: The expressions of
Toll-like receptor 9 and T-bet in circulating B and T cells in
newly diagnosed, untreated systemic lupus erythematosus and
correlations with disease activity and laboratory data in a Chinese
population. Immunobiology. 214:392–402. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Clancy RM, Markham AJ and Buyon JP:
Endosomal Toll-like receptors in clinically overt and silent
autoimmunity. Immunol Rev. 269:76–84. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Means TK, Latz E, Hayashi F, Murali MR,
Golenbock DT and Luster AD: Human lupus autoantibody-DNA complexes
activate DCs through cooperation of CD32 and TLR9. J Clin Invest.
115:407–417. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Papadimitraki ED, Choulaki C, Koutala E,
Bertsias G, Tsatsanis C, Gergianaki I, Raptopoulou A, Kritikos HD,
Mamalaki C, Sidiropoulos P and Boumpas DT: Expansion of toll-like
receptor 9-expressing B cells in active systemic lupus
erythematosus: Implications for the induction and maintenance of
the autoimmune process. Arthritis Rheum. 54:3601–3611. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Cervera R, Khamashta MA, Font J,
Sebastiani GD, Gil A, Lavilla P, Mejía JC, Aydintug AO,
Chwalinska-Sadowska H, de Ramón E, et al: Morbidity and mortality
in systemic lupus erythematosus during a 10-year period: A
comparison of early and late manifestations in a cohort of 1,000
patients. Medicine (Baltimore). 82:299–308. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Abu-Shakra M, Urowitz MB, Gladman DD and
Gough J: Mortality studies in systemic lupus erythematosus. Results
from a single center. II. Predictor variables for mortality. J
Rheumatol. 22:1265–1270. 1995.PubMed/NCBI
|
|
15
|
Abu-Shakra M, Urowitz MB, Gladman DD and
Gough J: Mortality studies in systemic lupus erythematosus. Results
from a single center. I. Causes of death. J Rheumatol.
22:1259–1264. 1995.PubMed/NCBI
|
|
16
|
Formiga F, Moga I, Pac M, Mitjavila F,
Rivera A and Pujol R: High disease activity at baseline does not
prevent a remission in patients with systemic lupus erythematosus.
Rheumatology (Oxford). 38:724–727. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hochberg MC: Updating the American College
of Rheumatology revised criteria for the classification of systemic
lupus erythematosus. Arthritis Rheum. 40:17251997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zen M, Bassi N, Nalotto L, Canova M,
Bettio S, Gatto M, Ghirardello A, Iaccarino L, Punzi L and Doria A:
Disease activity patterns in a monocentric cohort of SLE patients:
A seven-year follow-up study. Clin Exp Rheumatol. 30:856–863.
2012.PubMed/NCBI
|
|
19
|
Bombardier C, Gladman DD, Urowitz MB,
Caron D and Chang CH: Derivation of the SLEDAI. A disease activity
index for lupus patients. The Committee on Prognosis Studies in
SLE. Arthritis Rheum. 35:630–640. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Somerfield SD, Roberts MW and Booth RJ:
Double-stranded DNA antibodies: A comparison of four methods of
detection. J Clin Pathol. 34:1032–1035. 1981. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Haugbro K, Nossent JC, Winkler T,
Figenschau Y and Rekvig OP: Anti-dsDNA antibodies and disease
classification in antinuclear antibody positive patients: The role
of analytical diversity. Ann Rheum Dis. 63:386–394. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ng KP, Manson JJ, Rahman A and Isenberg
DA: Association of antinucleosome antibodies with disease flare in
serologically active clinically quiescent patients with systemic
lupus erythematosus. Arthritis Rheum. 55:900–904. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gladman DD, Urowitz MB and Keystone EC:
Serologically active clinically quiescent systemic lupus
erythematosus: A discordance between clinical and serologic
features. Am J Med. 66:210–215. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nikpour M, Urowitz MB, Ibañez D and
Gladman DD: Frequency and determinants of flare and persistently
active disease in systemic lupus erythematosus. Arthritis Rheum.
61:1152–1158. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tseng CE, Buyon JP, Kim M, Belmont HM,
Mackay M, Diamond B, Marder G, Rosenthal P, Haines K, Ilie V and
Abramson SB: The effect of moderate-dose corticosteroids in
preventing severe flares in patients with serologically active, but
clinically stable, systemic lupus erythematosus: Findings of a
prospective, randomized, double-blind, placebo-controlled trial.
Arthritis Rheum. 54:3623–3632. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nishimura M and Naito S: Tissue-specific
mRNA expression profiles of human toll-like receptors and related
genes. Biol Pharm Bull. 28:886–892. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chuang TH and Ulevitch RJ: Cloning and
characterization of a sub-family of human toll-like receptors:
HTLR7, hTLR8 and hTLR9. Eur Cytokine Netw. 11:372–378.
2000.PubMed/NCBI
|
|
29
|
Rao H, Zeng Q, Liang Y, Xiao C, Xie S and
Xu X: Correlation between TLR9 expression and cytokine secretion in
the clinical diagnosis of systemic lupus erythematosus. Mediators
Inflamm. 2015:7107202015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Komatsuda A, Wakui H, Iwamoto K, Ozawa M,
Togashi M, Masai R, Maki N, Hatakeyama T and Sawada K: Up-regulated
expression of Toll-like receptors mRNAs in peripheral blood
mononuclear cells from patients with systemic lupus erythematosus.
Clin Exp Immunol. 152:482–487. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mortezagholi S, Babaloo Z, Rahimzadeh P,
Namdari H, Ghaedi M, Gharibdoost F, Mirzaei R, Bidad K and Salehi
E: Evaluation of TLR9 expression on PBMCs and CpG ODN-TLR9 ligation
on IFN-α production in SLE patients. Immunopharmacol Immunotoxicol.
39:11–18. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kruse K, Janko C, Urbonaviciute V, Mierke
CT, Winkler TH, Voll RE, Schett G, Muñoz LE and Herrmann M:
Inefficient clearance of dying cells in patients with SLE:
Anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players.
Apoptosis. 15:1098–1113. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Nakano S, Morimoto S, Suzuki J, Nozawa K,
Amano H, Tokano Y and Takasaki Y: Role of pathogenic auto-antibody
production by Toll-like receptor 9 of B cells in active systemic
lupus erythematosus. Rheumatology (Oxford). 47:145–149. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Laustrup H, Voss A, Green A and Junker P:
SLE disease patterns in a Danish population-based lupus cohort: An
8-year prospective study. Lupus. 19:239–246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Medina-Quiñones CV, Ramos-Merino L,
Ruiz-Sada P and Isenberg D: Analysis of complete remission in
systemic lupus erythematosus patients over a 32-year period.
Arthritis Care Res (Hoboken). 68:981–987. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Qiu J, Shao S, Yang G, Shen Z and Zhang Y:
Association of Toll like receptor 9 expression with lymph node
metastasis in human breast cancer. Neoplasma. 58:251–255. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Anders HJ, Vielhauer V, Eis V, Linde Y,
Kretzler M, Perez de Lema G, Strutz F, Bauer S, Rutz M, Wagner H,
et al: Activation of toll-like receptor-9 induces progression of
renal disease in MRL-Fas (lpr) mice. FASEB J. 18:534–536. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
He B, Qiao X and Cerutti A: CpG DNA
induces IgG class switch DNA recombination by activating human B
cells through an innate pathway that requires TLR9 and cooperates
with IL-10. J Immunol. 173:4479–4491. 2004. View Article : Google Scholar : PubMed/NCBI
|
